Andrew Solomon, MD
Neurology · Burlington, VTNPI 1407091366
Payments from drug & device makers
Across 429 payments — averaging $4429.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$486K
- Novartis$412K
- Sanofi$389K
- Janssen Research & Development, LLC$223K
- Bristol Myers Squibb$156K
- Roche Products Limited$76K
- plus $158K from 14 others
Across 1 payment — averaging $7040.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Philips North America LLC$7K
What the payments were for
- Consulting fees$70,05249%
- Speaking & faculty fees$42,50730%
- Travel & lodging$25,45518%
- Food & beverage$3,2762%
- Education$1,1571%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 114 | $486,185 |
| Novartis | 5 | $411,783 |
| Sanofi | 52 | $389,009 |
| Janssen Research & Development, LLC | 18 | $223,343 |
| Bristol Myers Squibb | 21 | $155,627 |
| Roche Products Limited | 97 | $76,263 |
| EMD Serono, Inc. | 51 | $43,120 |
| Philips North America LLC | 6 | $40,467 |
| Merck Healthcare Kgaa | 6 | $22,796 |
| Genentech USA, Inc. | 16 | $15,081 |
| Amgen | 8 | $7,118 |
| E.r. Squibb & Sons, L.L.C. | 3 | $6,156 |
| Biogen | 9 | $5,696 |
| Greenwich Biosciences, Inc. | 1 | $5,412 |
| AstraZeneca | 14 | $4,699 |
| TG Therapeutics, Inc. | 3 | $3,628 |
| Merck Kgaa | 1 | $2,085 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $1,200 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $600 |
| Genentech, Inc. | 1 | $50 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,900,317 in reported general payments places this provider in the 95th percentile of 41 neurology providers in Vermont.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 51 | $431,041 |
| CopaxoneGlatiramer Acetate | 27 | $168,104 |
| TecfideraDimethyl Fumarate | 15 | $131,905 |
| Glatiramer Acetate | 29 | $109,027 |
| Dalfampridine ErDalfampridine | 49 | $46,545 |
| GlatopaGlatiramer Acetate | 28 | $45,777 |
| MyrbetriqMirabegron | 13 | $5,135 |
| Baclofen | 214 | $4,963 |
| Gabapentin | 138 | $2,644 |
| Tizanidine Hcl | 105 | $1,352 |
| Modafinil | 24 | $1,282 |
| Teriflunomide | 16 | $1,277 |
| AmantadineAmantadine Hcl | 16 | $744 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 31 | $580 |
| Levetiracetam | 12 | $448 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenTecfidera | $5,696 | $131,90515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 41 neurology providers in Vermont.
Other neurology in Burlington
- Peter CalabresiBurlington$3.6M
- James BoydBurlington$2.4M
- Rup TandanBurlington$514K
- Waqar WaheedBurlington$399K
- Alissa ThomasBurlington$155K
- Michael HehirBurlington$151K
- Adam Sprouse-BlumBurlington$130K
- Robert ShapiroBurlington$90K
- Chantal Roy-HewitsonBurlington$87K
- Lisa BakerBurlington$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.